MD Anderson Cancer Center
1515 Holcombe Boulevard
199 articles with MD Anderson Cancer Center
Research shows deadly tumors may be vulnerable to drugs that block their energy supply
Preclinical research finds new approach to treating aggressive cancer unresponsive to immunotherapy alone
2/15/2019There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
As the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) rolls on, companies are showcasing more data in presentations. BioSpace takes a look at some of the latest.
Immunotherapy combination generates responses against castration-resistant metastatic prostate cancer
Two checkpoint inhibitors provide early encouraging results for immunologically cold disease
Preclinical study identifies vulnerability in orphan cancers with SMARCB1 mutations, spurs launch of Phase II clinical trial
Researchers at The University of Texas MD Anderson Cancer Center have discovered an immune regulator that appears to dictate glioblastoma (GBM) progression by shutting down immune surveillance, indicating a potential new area of therapeutic investigation.
MD Anderson Cancer Center and Dragonfly Therapeutics announce strategic collaboration to take new immunotherapy candidates into clinical trials
The University of Texas MD Anderson Cancer Centerand Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly’s TriNKET™ (tri-specific natural killer cell engager therapy) immunotherapy drug candidates to patients in clinical trials beginning in 2019.
Complication rates and costs of invasive lung cancer diagnostic tests may be higher than anticipated
Study underscores importance of sharing risks with patients considering lung cancer screening
Comparison of pancreatic and melanoma tumors highlights importance of stroma
Gene signature may allow clinicians to better stratify patients and reduce treatment intensity to lower side effects
John Mendelsohn, M.D., president emeritus of The University of Texas MD Anderson Cancer Center and an internationally acclaimed leader in the field of medicine and scientist whose research helped pioneer a new type of cancer therapy, died Jan. 7 at his home in Houston.
MD Anderson Cancer Center and Nanobiotix announce a large-scale, comprehensive clinical collaboration on NBTXR3
Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix’s first-in-class agent NBTXR3 for use in treating six cancer types
MD Anderson Cancer Center and 4D pharma collaborate to evaluate live biotherapeutics in solid tumors
The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D’s live biotherapeutic oncology pipeline across a range of cancer settings.
Ascentage Pharma and MD Anderson Cancer Center Announce Strategic Alliance in Cancer Drug Development
Five-year collaboration aims to accelerate clinical development of select novel apoptosis-targeted and tyrosine kinase inhibitor product candidates
The Boston area, specifically Cambridge, has the highest concentration of biopharma companies in the U.S. That is followed rather closely by the San Francisco Bay Area. Many states want to encourage life science development—the return on investment can be very high, and the jobs they create are o...
Immuno-oncology comes pretty close to being a miracle cure for certain types of cancer. But it's not perfect, and a recently reported isolated case demonstrates that there are risks.
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
10/24/2018William H. Tettelbach, deputy chief medical officer of Marietta, Ga.-based MiMedx and lead author of the study, took time to speak with BioSpace about the research, which was published in the International Wound Journal.
This week will have moderate activity by the U.S. Food and Drug Administration (FDA). Although they jumped the gun on Regeneron and Sanofi’s cancer drug, there are still plenty of other decisions being made this week. Here’s a look.